Table 1 Baseline characteristics of the training set and validation set.
Variables | Total (N = 658) | Training (N = 461) | Validation (N = 197) | P |
|---|---|---|---|---|
Age (year) | 19.88 ± 4.15 | 19.72 ± 4.08 | 20.19 ± 4.28 | 0.236 |
Gender | 0.801 | |||
Female | 517 (78.57%) | 361 (78.31%) | 156 (79.19%) | |
Male | 141 (21.43%) | 100 (21.69%) | 41 (20.81%) | |
Body mass index | 21.9 ± 4.57 | 21.8 ± 4.71 | 22.2 ± 4.52 | 0.159 |
Marital status | 0.043 | |||
Unmarried | 598 (90.88%) | 426 (92.41%) | 172 (87.31%) | |
Married | 54 (8.21%) | 30 (6.51%) | 24 (12.18%) | |
Divorced | 6 (0.91%) | 5 (1.08%) | 1 (0.51%) | |
Education | 0.231 | |||
Primary school | 4 (0.61%) | 1 (0.22%) | 3 (1.52%) | |
Junior school | 152 (23.10%) | 104 (22.56%) | 48 (24.37%) | |
Senior school | 271 (41.19%) | 191 (41.43%) | 80 (40.61%) | |
College and above | 231 (35.11%) | 165 (35.79%) | 66 (33.50%) | |
Career | 0.948 | |||
Student | 483 (73.40%) | 337 (73.10%) | 146 (74.11%) | |
Employed | 98 (14.89%) | 70 (15.18%) | 28 (14.21%) | |
Unemployed | 77 (11.70%) | 54 (11.71%) | 23 (11.68%) | |
Duration of mental disease (month) | 39.31 ± 35.70 | 38.24 ± 34.22 | 41.82 ± 38.93 | 0.654 |
Psychiatric diagnosis (ICD-10) | 0.963 | |||
F20–F29 | 31 (4.71%) | 21 (4.56%) | 10 (5.08%) | |
F30–F39 | 409 (62.16%) | 288 (62.47%) | 121 (61.42%) | |
F40–F48 | 170 (25.84%) | 119 (25.81%) | 51 (25.89%) | |
F50–F59 | 10 (1.52%) | 6 (1.30%) | 4 (2.03%) | |
F90–F99 | 38 (5.78%) | 27 (5.86%) | 11 (5.58%) | |
Family history of mental illness | 0.630 | |||
None | 568 (86.32%) | 396 (85.90%) | 172 (87.31%) | |
Exist | 90 (13.68%) | 65 (14.10%) | 25 (12.69%) | |
Hospitalization (number) | 1.58 ± 1.01 | 1.57 ± 1.01 | 1.59 ± 1.03 | 0.822 |
Psycho-pharmaceutical medication use (month) | 10.92 ± 19.54 | 10.81 ± 20.59 | 11.17 ± 16.87 | 0.102 |
Suicide attempts history (number) | 0.289 | |||
0 | 426 (64.74%) | 302 (65.51%) | 124 (62.94%) | |
1 | 140 (21.28%) | 92 (19.96%) | 48 (24.37%) | |
2 | 55 (8.36%) | 40 (8.68%) | 15 (7.61%) | |
3 | 22 (3.34%) | 17 (3.69%) | 5 (2.54%) | |
4 | 11 (1.67%) | 7 (1.52%) | 4 (2.03%) | |
≥ 5 | 4 (0.61%) | 3 (0.65%) | 1 (0.51%) | |
Brøset violence checklist | 0.450 | |||
Low risk | 258 (39.21%) | 188 (40.78%) | 70 (35.53%) | |
Moderate risk | 289 (43.92%) | 197 (42.73%) | 92 (46.70%) | |
High risk | 111 (16.87%) | 76 (16.49%) | 35 (17.77%) | |
Antidepressant use | 0.014 | |||
None | 268 (40.73%) | 202 (43.82%) | 66 (33.50%) | |
Continuous use | 390 (59.27%) | 259 (56.18%) | 131 (66.50%) | |
Antipsychotic medications use | 0.574 | |||
None | 375 (56.99%) | 266 (57.70%) | 109 (55.33%) | |
Continuous use | 283 (43.01%) | 195 (42.30%) | 88 (44.67%) | |
Mood stabilizers use | 0.492 | |||
None | 527 (80.09%) | 366 (79.39%) | 161 (81.73%) | |
Continuous use | 131 (19.91%) | 95 (20.61%) | 36 (18.27%) | |
Sleep aids use | 0.064 | |||
None | 432 (65.65%) | 313 (67.90%) | 119 (60.41%) | |
Continuous use | 226 (34.35%) | 148 (32.10%) | 78 (39.59%) | |
Thyroxine level * | 0.525 | |||
Low | 76 (11.55%) | 53 (11.50%) | 23 (11.68%) | |
Normal | 579 (87.99%) | 405 (87.85%) | 174 (88.32%) | |
High | 3 (0.46%) | 3 (0.65%) | 0 (0.00%) | |
Adrenocorticotropic hormone level * | 0.711 | |||
Low | 24 (3.65%) | 17 (3.69%) | 7 (3.55%) | |
Normal | 610 (92.71%) | 429 (93.06%) | 181 (91.88%) | |
High | 24 (3.65%) | 15 (3.25%) | 9 (4.57%) | |
Prolactin level * | 0.400 | |||
Low | 13 (1.98%) | 8 (1.74%) | 5 (2.54%) | |
Normal | 261 (39.67%) | 190 (41.21%) | 71 (36.04%) | |
High | 384 (58.36%) | 263 (57.05%) | 121 (61.42%) | |
Plasma total cortisol level * | 0.154 | |||
Low | 106 (16.11%) | 73 (15.84%) | 33 (16.75%) | |
Normal | 507 (77.05%) | 362 (78.52%) | 145 (73.60%) | |
High | 45 (6.84%) | 26 (5.64%) | 19 (9.64%) | |
